Back to Dashboard
TAK · Healthcare

TAKEDA PHARMACEUTICAL CO LTD

Asia Healthcare Filing: 2025-12-31
Smart-money confidence · 1 of 3 sources firing
Bearish — money moving out

No standout activity across the feeds we track.

Hedge funds
20
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s.  ·  how the score works
◆ Next steps Interested in TAKEDA PHARMACEUTICAL CO LTD? Here's what to do with it.
Not financial advice. Bogen Capital surfaces public SEC filings — you decide what to do with them.
Market cap
$55.7B
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Exchange
NYSE
About TAKEDA PHARMACEUTICAL CO LTD

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig,…

Who's behind the signal
Every informed buyer we can see on TAK, across all three feeds.
Hedge funds · 4
D.E. Shaw & Co Increased +1426%
Citadel Advisors Increased +415%
AQR Capital Management Decreased −11%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar. TAKEDA PHARMACEUTICAL CO LTD isn't in the top-10 model right now, but 4 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
4
Investors
0
New positions
2
Increasing
2
Decreasing
0
Unchanged
Price History
Loading price data...
Return: High: Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.0×
Increased +1426%
% of portfolio
0.1%
Position change
+1426%
0.1% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
Increased +415%
% of portfolio
0.0%
Position change
+415%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
Decreased −11%
% of portfolio
0.0%
Position change
−11%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.0×
Decreased −65%
% of portfolio
0.0%
Position change
−65%
0.0% of Millennium Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to TAKEDA PHARMACEUTICAL CO LTD
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell TAKEDA PHARMACEUTICAL CO LTD or any security.

Get the Weekly Update

Every Sunday, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime